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disease while strikingly there was no signal in subjects without diabe-
tes. These ﬁndings, supported by independent studies (Mohammedi
et al., 2015), suggest that some individuals have a genetically-driven im-
pairment of anti-oxidant defenses that predispose them to cardiovascu-
lar disease in states of oxidant stress such as diabetes. What is currently
unknown is whether restoring anti-oxidant defenses in people thatCardiovascular disease continues to be the leading cause of death in
vascular disease.
Two points should be emphasized. First, despite the negative ﬁnd-
patients with Type-2 Diabetes Mellitus (T2D). Aggressive use of HMG-
CoA Reductase Inhibitors (statins) and blood pressure lowering agents
are showing signs of success as rates of coronary heart disease are on
the decline (Ali et al., 2013); however, a substantial amount of residual
risk remains suggesting that additional prevention strategies are need-
ed particularly in light of recent increases in the prevalence of T2D
(Gregg et al., 2007).
Treatments that block the damaging effects of oxidants have long
been considered as potential strategies to reduce the risk of cardiovas-
cular disease. Because redox signaling in the heart and other tissues
can have both physiological and pathological effects (Burgoyne et al.,
2012) any beneﬁt from anti-oxidant therapies may be limited. Indeed,
while Vitamin E showed beneﬁt in a mouse atherosclerosis model
(Pratico et al., 1998) and observational studies showed an inverse asso-
ciation of Vitamin E intake and cardiovascular disease (Jha et al., 1995),
randomized double blind placebo controlled trials do not support a ben-
eﬁt from Vitamin E, and even suggested harm (Lonn et al., 2005). The
discordant results of anti-oxidant clinical trials comparedwith observa-
tional and experimental studies raise many considerations including
whether clinical trials testing anti-oxidant compounds should target en-
rollment of subjects that have increased oxidant stress (Robinson et al.,
2006).
In this issue of EBioMedicine, Kobylecki et al. contribute to our under-
standing of the role of the natural anti-oxidant system plays in cardio-
vascular disease through their analysis of the Copenhagen General
Population Study and the Copenhagen City Heart Study (Kobylecki
et al., 2015). The authors studied a single nucleotide polymorphism in
the extracellular superoxide dismutase-3 gene (SOD3) that results in
the exchange of an amino acid causing the SOD3 peptide to not be
retained in the blood vessel wall. Diabetic individuals heterozygous forom.2015.11.026.
MA 02111, USA.
. This is an open access article undercarry the SOD3 polymorphism abrogates the additional risk of cardio-
ings of previous randomized clinical trials this study and others like it
should motivate the continued development and testing of novel anti-
oxidant compounds to prevent cardiovascular disease, particularly in
genetically susceptible individuals that have T2D. Second, genetic stud-
ies continue to identify meaningful insight into disease pathogenesis
when results from animal and clinical studies conﬂict.
We are on the verge of realizing the beneﬁts of PrecisionMedicine in
cancer therapy through the use of genetic information to guide treat-
ment selection (Collins and Varmus, 2015).While the current use of ge-
netics to guide the prevention of cardiovascular disease is in its infancy,
clinical trials that focus on genetically at risk individuals may have the
strongest ability to demonstrate a proof-of-principle for the potential
beneﬁts of novel treatments.
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